Renaissance Capital logo

Kaleido Biosciences Priced, Nasdaq: KLDO

Early-stage biotech developing oral microbiome therapies.

Industry: Health Care

Latest Trade: $8.31 0.00 (0.0%)

First Day Return: -5.1%

Return from IPO: -44.6%

Industry: Health Care

We are a clinical-stage healthcare company with a differentiated, chemistry-driven approach focused on leveraging the potential of the microbiome organ to treat disease and improve human health. We have built a human-centric proprietary product platform for discovery and development that we believe will enable the rapid advancement of a broad portfolio of novel product candidates into non-IND human clinical studies under regulations supporting research with food. Our product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. We have an industrialized approach to the discovery and development of MMTs, and our initial MMTs are targeted glycans. Each targeted glycan is an ensemble of complex carbohydrates that is intended to modulate microbial metabolism to drive a specific biological response. We believe our MMTs have the potential to be novel treatments across a variety of diseases and conditions.
more less
IPO News for Kaleido Biosciences
more
IPO Data
IPO File Date 01/11/2019
Offer Price $15.00
Price Range $20.00 - $22.00
Offer Shares (mm) 5.0
Deal Size ($mm) $75
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/27/2019
Offer Price $15.00
Price Range $20.00 - $22.00
Offer Shares (mm) 5.0
Deal Size ($mm) $75
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Lexington, MA
Founded 2015
Employees 118
Website www.kaleido.com